[Faricimab (visual impairment due to diabetic macular oedema) - Benefit assessment acc. to § 35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004306
Original Title: Faricimab (Visusbeeintraechtigung infolge eines diabetischen Makulaoedems)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Macular Edema
  • Diabetic Retinopathy
  • Angiogenesis Inhibitors
  • Intravitreal Injections
  • Antibodies, Monoclonal
  • Faricimab
  • Macular Edema
  • Benefit Assessment
  • NCT03622593
  • NCT03622580
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.